Crystals of laquinimod sodium and improved process for the manufacture thereof

a technology of laquinimod sodium and crystals, which is applied in the field of crystals of laquinimod sodium and improved process for the manufacture of thereof, can solve the problems of reducing the quality of crystalline characteristics and specifically tapped density

Inactive Publication Date: 2016-02-18
TEVA PHARMA IND LTD
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The process achieves a high-purity laquinimod sodium with desired particle size and density characteristics, reducing impurity levels and improving the pharmaceutical composition's stability and efficacy.

Problems solved by technology

However, this Example also shows reduced quality of crystalline characteristics, specifically Tapped Density.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystals of laquinimod sodium and improved process for the manufacture thereof
  • Crystals of laquinimod sodium and improved process for the manufacture thereof
  • Crystals of laquinimod sodium and improved process for the manufacture thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Discussion of Example 1

Example 1

[0596]The pilot scale process of recrystallization of laquinimod sodium was based on Example 15 of U.S. Pat. No. 7,884,208. The starting material was crude laquinimod sodium having low particle size (d(0.1)=1-2μ, d(0.5)=6-11μ; d(0.9)=20-35μ) and appears as aggregated solid. Example 15 of U.S. Pat. No. 7,884,208 involves 25.0 g of laquinimod sodium (laboratory scale) prepared according to the method disclosed in U.S. Pat. No. 6,875,869. In Example 15, the 25.0 g of laquinimod sodium is dissolved in an aqueous solution of laquinimod sodium and then evaporated under vacuum at stirring to a concentrated solution having a volume ratio of 2.14 v / w, the resulting residue is seeded to induce crystallization then treated with an anti-solvent (acetone).

[0597]The modified pilot scale process was performed with 2.5 kg of laquinimod sodium which is a 100-fold scale up from Example 15. In addition, the modified pilot scale process had significant differences from t...

example 2

Recrystallization of Laquinimod SodiumLaboratory Scale (Laboratory Scale Batch A)

[0602]Recrystallization of laquinimod sodium was performed on laboratory scale (Batch A) as follows.

[0603]All operations of Laquinimod Na re-crystallization step including evaporation were performed on laboratory scale in transparent agitated glass reactors equipped with stirrer, thermometers and circulating bath for heating and cooling.

[0604]25 g crude Na Laquinimod and 275 ml deionized water introduced into 250 ml stirred jacketed glass reactor. The mixture is stirred and heated to 70° C., after complete dissolution of the solid the solution is filtered through paper filter. Resulting clear filtrate introduced to 250 ml jacketed glass reactor equipped with circulating bath, stirrer, thermometer and vacuum distillation system.

[0605]Vacuum is applied and water is distilled at stirring, pressure during the evaporation is 38-40 mbar and jacket temperature is 55° C.

[0606]After distillation of ca. ⅔ volume...

example 3

Recrystallization of Laquinimod SodiumLaboratory Scale (Laboratory Scale Batch B)

[0615]Recrystallization of laquinimod sodium was performed on laboratory scale (Batch B) as follows.

[0616]All operations of Laquinimod Na re-crystallization step including evaporation were performed on laboratory scale in transparent agitated glass reactors equipped with stirrer, thermometers and circulating bath for heating and cooling.

[0617]25 g Na Laquinimod crude and 275 ml deionized water introduced into 250 ml stirred jacketed glass reactor. The mixture is stirred and heated to 70° C., after complete dissolution of the solid the solution is filtered through paper filter. Resulting clear filtrate introduced to 250 ml jacketed glass reactor equipped with circulating bath, stirrer, thermometer and vacuum distillation system. Vacuum is applied and water is distilled at stirring, pressure during the evaporation is 38-40 mbar and jacket temperature is 55° C. During the distillation spontaneous crystall...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The subject invention provides a mixture of Crystalline Laquinimod sodium particles, wherein (i) ≧90% of the total amount by volume of the laquinimod sodium particles have a size of ≦̸40 μm or (ii) ≧50% of the total amount by volume of the laquinimod sodium particles have a size of ≦̸15 μm and wherein: a) the mixture has a bulk density of 0.2-0.4 g / mL; b) the mixture has a tapped density of 0.40-0.7 g / mL; c) an amount of heavy metal in the mixture is no more than 20 ppm relative to the amount by weight of laquinimod sodium; d) an amount of MCQ in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; e) an amount of MCQCA in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; or f) an amount of MCQME in the mixture is no more than 0.12% relative to the amount of laquinimod sodium as measured by HPLC. The subject invention also provides a pharmaceutical composition comprising an amount of laquinimod and at least one of BH-3-HKAQ, MCQ, MCQCA, MCQME, NEA, and MCQEE. The subject invention also provides processes for preparing BH-3-HLAQ, MCQ, MCQCA, MCQEE, and compounds prepared by said processes. Further provided is a process for testing whether a sample of laquinimod contains an undesirable impurity. Further provided is a process for preparing a validated pharmaceutical composition comprising laquinimod, for preparing a pharmaceutical composition comprising laquinimod, or for distributing a validated batch of a pharmaceutical composition comprising laquinimod, for validating a batch of a pharmaceutical product containing laquinimod and a pharmaceutically acceptable carrier for distribution, and for preparing a packaged pharmaceutical composition comprising laquinimod, each comprising determining the amount of at least one of BH-3-HLAO, MCQ, MCQCA, MCQME<NEA, and MCQEE in a sample or batch. The subject invention further provides use of BH-3-HLAQ, MCQ, MCQCA, MCQME, MCQEE as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition composing laquinimod. Finally, the subject invention provides methods of ddenrrining the concentration of BH-3-HLAQ, MCQ, MCQCA, MCQME, MCQE<5-HLAQ, SPIRO-LAQ or H-LAQ in a pharmaceutical composition composing laquinimod.

Description

[0001]This application claims priority of U.S. Provisional Application No. 61 / 785,575, filed Mar. 14, 2013, the entire content of which is hereby incorporated by reference herein.[0002]Throughout this application, various publications are referred to by first author and year of publication. Full citations for these publications are presented in a References section immediately before the claims. Disclosures of the publications cited in the References section in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as of the date of the invention described herein.BACKGROUND OF THE INVENTION[0003]Laquinimod is a compound which has been shown to be effective in the acute experimental autoimmune encephalomyelitis (aEAE) model (U.S. Pat. No. 6,077,851). Its chemical name is N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, and its Chemical Registry number is 248281-84-7.[0004]...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): G01N30/06C07D215/56G01N33/15
CPCC07D215/56C07B2200/13G01N30/06G01N33/15C07C235/16A61K31/47A61P1/04A61P13/12A61P19/02A61P25/00A61P25/24A61P27/02A61P29/00A61P37/06
InventorFRENKEL, ANTONLAXER, AVITALIOFFE, VLADIMIRJANSSON, KARL-ERIKFRISTEDT, ULF TOMAS
OwnerTEVA PHARMA IND LTD